Korean ADC players are trying to build an ecosystem amid an “imbalance” in demand and supply of technology, stemming from a relatively small pool of developers of ADC therapeutics and new target/antibody providers.
Pinotbio is developing multiple ADC pipelines based on proprietary ADC platform PINOT-ADC, which is said to have outstanding competitiveness in terms of meeting the industry trends of strong camptothecin payloads and hydrophilic linker-based ADC platforms.
In the short term, it plans to provide ADC platform technology to partners to generate sustainable cash flows, while in the longer-term, it will seek in-house development of first-in-class and best-in-class drug candidates.

How Pinotbio Is Helping Build Korea's ADC Ecosystem

'Imbalance' In Technology Demand/Supply